Dr Helen Parry MBChB, MSc, PhD, MRCP, FRCPath

Dr Helen Parry

Institute of Immunology and Immunotherapy
Associate Professor

Contact details

Institute of Immunology and Immunotherapy
Cancer Sciences Building
Mindelsohn Way
University of Birmingham
B15 2TT

Dr Helen Parry is an Associate Professor at The University of Birmingham and honorary consultant at the Queen Elizabeth Hospital, Birmingham. She has received funding from The Wellcome Trust (PhD fellowship), Academy of medical sciences (current), British Society of Haematology (current) and Queen Elizabeth Hospital charity (current education grant) funding and completed her NIHR academic clinical lecturership in 2021.

Her current research areas include secondary immunodeficiency in haematological malignancies, and in particular Chronic Lymphocytic Leukaemia (CLL), for which she co-authored the British clinical guidelines. Her work involves studying patient immunity and the impact of novel therapies used to treat CLL and how we can improve current vaccination strategies to minimise infection risk. She is also interested in optimising the delivery of haematology services within a primary care setting and has an interest in medical education, being the co-founder of Blooducation. 


  • FRCPath 2018
  • PhD, University of Birmingham 2016
  • MRCP (UK) 2009
  • MBChB (Hons) University of Birmingham 2006
  • MSc (Distinction) in pathological studies, University of Birmingham 2005


  • MBChB programme – Immunology and infection module; cancer module
  • Supervisor for intercalating BSc students


Research themes:

  • Optimising vaccination strategies and minimising infection risk in patients with CLL
  • Investigating immunity in the setting of novel therapeutic agents


Recent publications


Parry, H, Moss, P, Stephens, C, Bentley, C, Brown, K, Amirthalingam, G, Hallis, B, Otter, A, Zuo, J & Moss, P 2022, 'Extended interval BNT162b2 vaccination enhances peak antibody generation', NPJ vaccines, vol. 7, no. 1, 14. https://doi.org/10.1038/s41541-022-00432-w

Parry, H, McIlroy, G, Moss, P, Damery, S, Tyson, G, Logan, N, Davis, C, Willett, B, Zuo, J, Ali, M, Kaur, M, Stephens, C, Brant, D, Otter, A, McSkeane, T, Rolfe, H, Faustini, S, Richter, A, Lee, S, Wandroo, F, Shafeek, S, Pratt, G, Paneesha, S & Moss, P 2022, 'Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia', Journal of Hematology and Oncology, vol. 15, no. 1, 3. https://doi.org/10.1186/s13045-021-01219-7

Tye, E, Jinks, E, Haigh, T, Kaul, B, Patel, P, Parry, H, Newby, M, Crispin, M, Kaur, N, Moss, P, Drennan, S, Taylor, G & Long, H 2022, 'Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition', Nature Immunology, vol. 23, pp. 1726–1734. https://doi.org/10.1038/s41590-022-01351-7

Parry, H, Bruton, R, Ayodele, R, Sylla, P, McIlroy, G, Logan, N, Scott, S, Nicol, S, Verma, K, Stephens, C, Willett, B, Zuo, J & Moss, P 2022, 'Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people', Cell Reports Medicine, vol. 3, no. 9, 100739. https://doi.org/10.1016/j.xcrm.2022.100739

Parry, H, McIlroy, G, Bruton, R, Ali, M, Stephens, C, Damery, S, Otter, A, McSkeane, T, Rolfe, H, Faustini, S, Wall, N, Hillmen, P, Pratt, G, Paneesha, S, Zuo, J, Richter, A & Moss, P 2021, 'Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia', Blood Cancer Journal, vol. 11, no. 7, 136. https://doi.org/10.1038/s41408-021-00528-x

Parry, H, Bruton, R, Stephens, C, Brown, K, Amirthalingam, G, Otter, A, Hallis, B, Zuo, J & Moss, P 2021, 'Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people', Immunity & Ageing, vol. 18, no. 1, 34. https://doi.org/10.1186/s12979-021-00246-9

Parry, H, Bruton, R, Tut, G, Ali, M, Stephens, C, Greenwood, D, Faustini, S, Hughes, S, Huissoon, A, Meade, R, Brown, K, Amirthalingam, G, Otter, A, Hallis, B, Richter, A, Zuo, J & Moss, P 2021, 'Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis', The Lancet Healthy Longevity, vol. 2, no. 9, pp. e554-e560. https://doi.org/10.1016/S2666-7568(21)00169-0

Parry, HM, Dowell, AC, Zuo, J, Verma, K, Kinsella, FAM, Begum, J, Croft, W, Sharma-Oates, A, Pratt, G & Moss, P 2021, 'PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity', PLoS pathogens, vol. 17, no. 3, e1009349. https://doi.org/10.1371/journal.ppat.1009349

Subbarao, S, Warrener, LA, Hoschler, K, Perry, KR, Shute, J, Whitaker, H, O’brien, M, Baawuah, F, Moss, P, Parry, H, Ladhani, SN, Ramsay, ME, Brown, KE & Amirthalingam, G 2021, 'Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021', Eurosurveillance, vol. 26, no. 12, 2100329. https://doi.org/10.2807/1560-7917.ES.2021.26.12.2100329

Parry, H, Tut, G, Bruton, R, Faustini, S, Stephens, C, Saunders, P, Bentley, C, Hilyard, K, Brown, K, Amirthalingam, G, Charlton, S, Leung, S, Chiplin, E, Coombes, NS, Bewley, KR, Penn, EJ, Rowe, C, Otter, A, Watts, R, D'Arcangelo, S, Hallis, B, Makin, A, Richter, A, Zuo, J & Moss, P 2021, 'mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant', eLife, vol. 10, e69375. https://doi.org/10.7554/eLife.69375

Mato, AR, Roeker, LE, Jacobs, R, Hill, BT, Lamanna, N, Brander, D, Shadman, M, Ujjani, CS, Yazdy, MS, Perini, GF, Pinilla-ibarz, JA, Barrientos, J, Skarbnik, AP, Torka, P, Pu, JJ, Pagel, JM, Gohil, S, Fakhri, B, Choi, M, Coombs, CC, Rhodes, J, Barr, PM, Portell, CA, Parry, H, Garcia, CA, Whitaker, KJ, Winter, AM, Sitlinger, A, Khajavian, S, Grajales-cruz, AF, Isaac, KM, Shah, P, Akhtar, OS, Pocock, R, Lam, K, Voorhees, TJ, Schuster, SJ, Rodgers, TD, Fox, CP, Martinez-calle, N, Munir, T, Bhavsar, EB, Bailey, N, Lee, JC, Weissbrot, HB, Nabhan, C, Goodfriend, JM, King, AC, Zelenetz, AD, Dorsey, C, Bigelow, K, Cheson, BD, Allan, JN & Eyre, TA 2020, 'Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy', Clinical Cancer Research, vol. 26, no. 14, pp. 3589-3596. https://doi.org/10.1158/1078-0432.CCR-19-3815

Paneesha, S, Pratt, G, Parry, H & Moss, P 2020, 'Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia', Leukemia Research, vol. 93, pp. 106366. https://doi.org/10.1016/j.leukres.2020.106366

Parry, HM, Mcilroy, G, Bruton, R, Damery, S, Tyson, G, Logan, N, Davis, C, Willett, B, Zuo, J, Ali, M, Kaur, M, Stephens, C, Brant, D, Otter, A, Mcskeane, T, Rolfe, H, Faustini, S, Richter, AG, Lee, S, Wandroo, F, Shafeek, S, Pratt, G, Paneesha, S & Moss, P 2020, 'Impaired Neutralisation of SARS-CoV-2 Delta Variant in Vaccinated Patients With B Cell Chronic Lymphocytic Leukaemia', SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3941045


Parry, H, Bruton, R, Roberts, T, Mcilroy, G, Damery, S, Sylla, P, Dowell, AC, Tut, G, Lancaster, T, Bone, D, Willett, B, Logan, N, Scott, S, Hulme, S, Jadir, A, Amin, U, Nicol, S, Stephens, C, Faustini, S, Al-taei, S, Richter, A, Blakeway, D, Verma, K, Margielewska-davies, S, Pearce, H, Pratt, G, Zuo, J, Paneesha, S & Moss, P 2022, 'COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia', Cancer Cell, vol. 40, no. 6, pp. 584-586. https://doi.org/10.1016/j.ccell.2022.05.001

Ebanks, D, Faustini, S, Shields, A, Parry, H, Moss, P, Plant, T, Richter, A & Drayson, M 2021, 'Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays', Journal of Infection, vol. 83, no. 4, pp. e18-e20. https://doi.org/10.1016/j.jinf.2021.07.020

View all publications in research portal